Acerta Pharma BV — Biomedical Watch V2

Traitements3programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Acalabrutinib (ACP-196)This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).	Cancer	Phase 3	À vérifier	United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, …	À vérifier
IdelalisibThe purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).	Cancer	Phase 3	Immunomodulation	United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, …	À vérifier
Acalabrutinib (ACP-196)This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).	Cancer	Phase 3	À vérifier	United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, France, Germany, Hong Kong, Hungary, Israel, Italy, New Zealand, Poland, Russia, Singapore, Slovakia, South Korea, …	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Acalabrutinib (ACP-196)	Cancer	Phase 3	NCT02970318	A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL	ACTIVE_NOT_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.